The developments in science and technology mean that Complex Innovative Design (CID) trials are needed to assess new medicines, in different (often smaller, more specific) patient populations. We can and should look to be more efficient in how we assess new medicines. Being able to offer the UK as a place where innovative clinical trials are welcomed and supported by regulations and infrastructure will be a competitive advantage for the UK.
Despite being a key area, there was a need to gather more evidence to support policy development. The MISG CRWG group conducted a survey in June 2018 to collate information about CID trials. This included responses gathered from industry, MHRA, NIHR, MRC and the NHS. This report was prepared for, and submitted to, the UK Government’s Office for Life Sciences in September 2018.